Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

IN ACCORDANCE WITH ARTICLES L.233-8 II OF THE FRENCH COMMERCIAL CODE AND 223-16 OF THEGENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY (AUTORIT DES MARCHS FINANCIERS)

VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY

PARIS AND CAMBRIDGE, MASS., DEC. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY PIONEERING PHYSICS-BASED APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, TODAY ANNOUNCED THAT FOLLOWING THE ANNUAL REVIEW OF THE EURONEXT PARIS INDICES, THE SCIENTIFIC COUNCIL OF THE INDICES HAS DECIDED TO ADMIT NANOBIOTIX TO BOTH THE CAC MID 60 AND SBF 120 INDICES.

NANOBIOTIX TO JOIN CAC MID 60 AND SBF 120 INDICES ON EURONEXT PARIS

PARIS AND CAMBRIDGE, MASS., NOV. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY PIONEERING PHYSICS-BASED APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, TODAY REPORTED AN OPERATIONAL UPDATE AND FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2025 ALONG WITH AN OUTLOOK FOR CLINICAL UPDATES FROM STUDIES SPONSORED BY NANOBIOTIX OR THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (MD ANDERSON) EXPECTED IN 2026 AND ANNOUNCED THE CLOSING OF ITS NON-DILUTIVE ROYALTY FINANCING TRANSACTION WITH HCRX.

NANOBIOTIX PROVIDES THIRD QUARTER 2025 OPERATIONAL AND FINANCIAL UPDATE ALONG WITH 2026 CLINICAL OUTLOOK

PARIS AND CAMBRIDGE, MASS., NOV. 13, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY PIONEERING PHYSICS-BASED APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, TODAY ANNOUNCED ADVANCEMENTS FOR ITS NEXT-WAVE CURADIGM NANOPRIMER PLATFORM.

NANOBIOTIX ANNOUNCES CURADIGM NANOPRIMER PLATFORM ADVANCEMENTS WITH UPDATED PLANS FOR INTERNAL PIPELINE DEVELOPMENT AND EXTERNAL COLLABORATIONS

PARIS AND CAMBRIDGE, MASS., NOV. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO - NASDAQ: NBTX - THE COMPANY), A LATE-CLINICAL STAGE BIOTECHNOLOGY COMPANY PIONEERING NANOTHERAPEUTIC APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, ANNOUNCED TODAY THAT COMPANY MANAGEMENT WILL PARTICIPATE IN FIRESIDE CHATS AT FOLLOWING CONFERENCES:

NANOBIOTIX TO PARTICIPATE IN INVESTOR CONFERENCES THE WEEK OF NOVEMBER 10TH

PARIS AND CAMBRIDGE, MASS., OCT. 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY PIONEERING PHYSICS-BASED APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A ROYALTY-BASED FINANCING AGREEMENT WITH HEALTHCARE ROYALTY (HCRX), PROVIDING UP TO $71 MILLION IN NON-DILUTIVE CAPITAL AND ESTABLISHING THE FINANCIAL FOUNDATION FOR SELF-SUSTAINABILITY AND THE ADVANCEMENT OF NEXT WAVE NANOTHERAPEUTIC PLATFORMS FOR LONG-TERM GROWTH.

NANOBIOTIX ANNOUNCES STRATEGIC ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY FOR UP TO $71 MILLION AND EXTENDS CASH RUNWAY TOWARD LONG-TERM GROWTH

DATA PRESENTED AT THE 2025 ANNUAL MEETING OF THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) ON OCTOBER 1 ST

NANOBIOTIX ANNOUNCES FIRST DATA FROM PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) FOR PATIENTS WITH ESOPHAGEAL CANCER

PARIS AND CAMBRIDGE, MASS., SEPT. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO - NASDAQ: NBTX - THE COMPANY), A LATE-CLINICAL STAGE BIOTECHNOLOGY COMPANY PIONEERING NANOTHERAPEUTIC APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, PROVIDED AN UPDATE ON OPERATIONAL PROGRESS AND ANNOUNCED ITS HALF YEAR FINANCIAL RESULTS FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2025.

NANOBIOTIX PROVIDES BUSINESS UPDATE AND REPORTS HALF YEAR 2025 FINANCIAL RESULTS

DATA PRESENTED AS A TOP-RATED ABSTRACT IN HEAD AND NECK CANCER AT THE 2025 ANNUAL MEETING OF THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) ON SEPTEMBER 29TH

NANOBIOTIX ANNOUNCES UPDATED PHASE 1 RESULTS CONTINUING TO SUPPORT JNJ-1900 (NBTXR3) PLUS ANTI-PD-1 AS A POTENTIAL NEW 1L OR 2L+ OPTION IN ANTI-PD-1 NAVE OR RESISTANT R/M-HNSCC

DATA SHOW A FAVORABLE SAFETY PROFILE AND EARLY EFFICACY SIGNALS IN A HEAVILY PRE-TREATED POPULATION WHOSE CANCER PROGRESSED AFTER MULTIPLE PRIOR LINES OF THERAPY INCLUDING ANTI-PD-1 RECOMMENDED PHASE 2 DOSE (RP2D) ESTABLISHED AT 33% OF GROSS TUMOR VOLUME (GTV) 47.4% (9/19) BEST OBSERVED OBJECTIVE RESPONSE RATE (ORR) IN ALL LESIONS PER RECIST 1.1 78.9% (15/19) BEST OBSERVED DISEASE CONTROL RATE (DCR) IN ALL LESIONS PER RECIST 1.1 14.6 MONTHS MEDIAN OVERALL SURVIVAL (MOS) IN ALL PATIENTS TREATED (N=21) INVESTIGATORS CONCLUDED THAT THESE DATA WARRANT FURTHER INVESTIGATION IN RANDOMIZED CLINICAL TRIALS AS A POTENTIAL NEW OPTION FOR PATIENTS WITH PRIMARY CUTANEOUS MELANOMA NAVE OR REFRACTORY TO ANTI-PD-1 NANOBIOTIX WILL HOST A CONFERENCE CALL TO DISCUSS THE DATA ON SEPTEMBER 18, 2025 AT 8:00AM EDT/ 2:00PM CEST DATA PRESENTED ON SEPTEMBER 17 AT THE 2025 IMMUNORAD CONFERENCE PARIS AND CAMBRIDGE, MASS., SEPT. 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-CLINICAL STAGE BIOTECHNOLOGY COMPANY PIONEERING NANOTHERAPEUTIC APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, TODAY ANNOUNCED NEW RESULTS FOCUSED ON PATIENTS WITH PRIMARY CUTANEOUS MELANOMA FROM THE ONGOING PHASE 1 STUDY 1100 EVALUATING JNJ-1900 (NBTXR3) IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (PEMBROLIZUMAB OR NIVOLUMAB) FOR PATIENTS WITH ADVANCED CANCERS.

NANOBIOTIX ANNOUNCES NEW RESULTS FROM A PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS AS A 2L+ THERAPY FOR PATIENTS WITH PRIMARY CUTANEOUS MELANOMA RESISTANT TO ANTI-PD-1

PARIS AND CAMBRIDGE, MASS., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-CLINICAL STAGE BIOTECHNOLOGY COMPANY PIONEERING NANOPARTICLE-BASED APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, ANNOUNCED TODAY THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT FOLLOWING CONFERENCE:

NANOBIOTIX TO PARTICIPATE IN THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

PARIS AND CAMBRIDGE, MASS., JULY 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY PIONEERING PHYSICS-BASED APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED TWO IMPORTANT DEVELOPMENTS THAT AIM TO REINFORCE THE GLOBAL POSITIONING OF POTENTIAL FIRST-IN-CLASS RADIOENHANCER JNJ-1900 (NBTXR3), WHICH IS LICENSED BY JANSSEN PHARMACEUTICA NV, A JOHNSON & JOHNSON COMPANY.

Nanobiotix S.A.

NBTX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Nanobiotix S.A.

NBTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NBTX